Eli Lilly and Company (ETR:LLY)
655.20
-10.60 (-1.59%)
Aug 1, 2025, 5:35 PM CET
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $12.73B USD in the quarter ending March 31, 2025, with 45.17% growth. This brings the company's revenue in the last twelve months to $49.00B, up 36.38% year-over-year. In the year 2024, Eli Lilly and Company had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$49.00B
Revenue Growth
+36.38%
P/S Ratio
13.07
Revenue / Employee
$1.04M
Employees
47,000
Market Cap
592.73B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
Eli Lilly and Company News
- 14 hours ago - Why Eli Lilly Stock Topped the Market Today - The Motley Fool
- 16 hours ago - Weight-loss drugs may be coming to Medicare, Medicaid under experimental program - Market Watch
- 17 hours ago - Trim Your AI Stocks And Buy Eli Lilly - Seeking Alpha
- 20 hours ago - Eli Lilly: The Best Growth Prospects Come At A Price - Seeking Alpha
- 21 hours ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 21 hours ago - Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients - Benzinga
- 1 day ago - Eli Lilly: The Worst May Be Already Over (Earnings Preview) - Seeking Alpha
- 1 day ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes